国家: 美国
语言: 英文
来源: NLM (National Library of Medicine)
DACTINOMYCIN (UNII: 1CC1JFE158) (DACTINOMYCIN - UNII:1CC1JFE158)
XGen Pharmaceuticals DJB, Inc.
INTRAVENOUS
PRESCRIPTION DRUG
Dactinomycin for injection is indicated for the treatment of adult and pediatric patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen. Dactinomycin for injection is indicated for the treatment of adult and pediatric patients with rhabdomyosarcoma, as part of a multi-phase, combination chemotherapy regimen. Dactinomycin for injection is indicated for the treatment of adult and pediatric patients with Ewing sarcoma, as part of a multi-phase, combination chemotherapy regimen. Dactinomycin for injection is indicated for the treatment of adult and pediatric patients with metastatic, nonseminomatous testicular cancer, as part of a multi-phase, combination chemotherapy regimen. Dactinomycin for injection is indicated for the treatment of post-menarchal patients with gestational trophoblastic neoplasia, as a single agent or as part of a combination chemotherapy regimen. Dactinomycin for injection is indicated for the treatment of adult patients with locally recurrent or locoregional s
Dactinomycin for injection for intravenous use is supplied as a sterile, amorphous yellow to orange, lyophilized powder in a single-dose vial. Each Dactinomycin for injection vial (NDC 39822-2100-2) contains 0.5 mg of dactinomycin and 20 mg of mannitol. Store at 20 to 25ºC (68 to 77ºF); excursions permitted between 15 to 30ºC (59 to 86ºF) [see USP Controlled Room Temperature]. Protect Dactinomycin for injection from light and humidity. Store the reconstituted Dactinomycin for injection at room temperature for no more than 4 hours from reconstitution to completion of administration [see Dosage and Administration (2.7)] . Dactinomycin for injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.1 NDC Single Vial Cartons NDC 39822-2100-2
Abbreviated New Drug Application
DACTINOMYCIN- DACTINOMYCIN INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION XGEN PHARMACEUTICALS DJB, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE DACTINOMYCIN FOR INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR DACTINOMYCIN FOR INJECTION. DACTINOMYCIN FOR INJECTION FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1964 RX ONLY RECENT MAJOR CHANGES Dosage and Administration, Recommended Dosage for Wilms Tumor (2.1) 8/2018 Dosage and Administration, Recommended Dosage for Ewing Sarcoma (2.3) 8/2018 INDICATIONS AND USAGE Dactinomycin for injection is an actinomycin indicated for the treatment of: adult and pediatric patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen. (1.1) adult and pediatric patients with rhabdomyosarcoma, as part of a multi-phase, combination chemotherapy regimen. ( 1.2) adult and pediatric patients with Ewing sarcoma, as part of a multi-phase, combination chemotherapy regimen. (1.3) adult and pediatric patients with metastatic, nonseminomatous testicular cancer, as part of a multi- phase, combination chemotherapy regimen. (1.4) post-menarchal patients with gestational trophoblastic neoplasia, as a single agent or as part of a combination chemotherapy regimen. (1.5) adult patients with locally recurrent or locoregional solid malignancies, as a component of palliative or adjunctive regional perfusion. (1.6) DOSAGE AND ADMINISTRATION Wilms Tumor: The recommended dose is 45 mcg/kg intravenously once every 3 to 6 weeks for up to 26 weeks, as part of a multi-agent combination chemotherapy regimen. (2.1) Rhabdomyosarcoma: The recommended dose is 15 mcg/kg intravenously once daily for 5 days every 3 to 9 weeks for up to 112 weeks, as part of a multi-agent combination chemotherapy regimen. (2.2) Ewing Sarcoma: The recommended dose is 1250 mcg/m intravenously once every 3 weeks for 51 weeks, as part of a multi-agent combination chemotherapy regimen. (2.3) Metastatic Nonseminomatous Tes 阅读完整的文件